Drug Trial Radar · NCT02684708
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,921
Actual
Start
Oct 1, 2015
Primary completion
Oct 31, 2024
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- University of GiessenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide
- First posted
- Feb 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
Conditions
- Classical Hodgkin Lymphoma
Interventions
cyclophosphamide, vincristine, prednisone, dacarbazineDrug
28-day chemotherapy cycle
cyclo, vcr, pred, dacarb,etop and doxoDrug
21-day chemotherapy cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: 5 years
Locations
19 sites in 19 countries. Site status is shown where the registry gives one.
Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital
Victoria Park, Australia
St. Anna Kinderspital
Vienna, Austria
Paediatric haemato-oncology, University Hospitals of Leuven
Leuven, Belgium
Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol
Prague, Czechia
Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen
Copenhagen, Denmark
Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau
Paris, France
Justus Liebig University of Giessen
Giessen, Germany
Our Lady's Children's Hospital, Crumlin
Dublin, Ireland
Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division
Petah Tikva, Israel
Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS
Aviano, Italy
Princess Máxima Center for pediatric oncology
Utrecht, Netherlands
Starship Blood and Cancer Centre, Starship Children's Hospital
Auckland, New Zealand
Department of Medical Oncology Oslo University Hospital
Oslo, Norway
Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty
Krakow, Poland
Clinic of Pediatric Oncology University Children's Hospital
Bratislava, Slovakia
Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío
Seville, Spain
Pediatric Hematology & Oncology Children´s University Hospital
Uppsala, Sweden
CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique
Lausanne, Switzerland
University College London Hospitals
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.